Clinical trials: Hematopoietic Malignancy
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer Survivors
This clinical trial studies whether an artificial intelligence (AI)-powered supportive care chatbot is helpful for addressing the supportive care needs of young adult cancer survivors.
- Trial name
- NCT07772596
- Testing
- Artificial Intelligence-based Intervention, Interview, Survey Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Leukemia, Hematopoietic and Lymphoid System Neoplasm
Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study
This clinical trial tests how well a pain management intervention preparatory to a future pragmatic trial works in rural dwelling and Hispanic cancer survivors.
- Conditions
- Chronic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Lymphoma, Malignant Solid Neoplasm
- Trial name
- NCT06063603
- Testing
- Acupuncture Therapy, Cancer Pain Management, Cognitive Behavior Therapy
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Mayo Clinic
Hematologic Neoplasms
Prophylactic Early PN in HPT/BMT
Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished.
- Trial name
- NCT03083327
- Testing
- Parenteral nutrition., Pragmatic standard care.
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 408 people
- Sponsor
- University of Sydney
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Cannabis Use Patterns Among Cancer Patients
This study determines patterns of cannabis use among cancer patients. Information collected in this study may help doctors to understand patient use of cannabis therapy, their knowledge and experiences with this therapy, benefits…
- Trial name
- NCT05132842
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 1,568 people
- Sponsor
- Thomas Jefferson University
Hematopoietic/Lymphoid Cancer, Psychological Disorder
Feasibility Study of a Diary for Allogenic Hematopoietic Stem Cell Transplantation Patients and Families
Allogenic hematopoietic stem cell transplantation is a specific time during hematological disease management for the patients, theirs relatives and the healthcare team.
- Trial name
- JACintHE (NCT04172818)
- Testing
- quality of life questionnaire
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
This is a prospective, open-label, nonrandomized, prospective clinical trial evaluating a fixed regimen of treosulfan, fludarabine and low-dose total body irradiation (TBI) in children with acute myeloid leukemia (AML) and…
- Trial name
- NCT01772953
- Testing
- Treosulfan
- Where
- 23 sites in United States
- Volunteers
- 40 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Haemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is Warranted
Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies
Recent advances in allogeneic hematopoietic cell transplantation (allo-SCT) have led to reduce intensity preparative regimens that are non-myeloablative and reduce the toxicities associated with the transplant.
- Trial name
- TLI-ATG (NCT01566656)
- Testing
- total lymphoid irradiation and anti-thymocyte globulin
- Where
- 4 sites in France
- Volunteers
- 15 people
- Sponsor
- Nantes University Hospital
Malignant Lymphoma, Stem Cell Type, Autologous Transplant
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
The purpose of this study is to determine if the combination of G-CSF and bortezomib is safe and effective in blood cell mobilization.
- Trial name
- NCT01171092
- Testing
- bortezomib and G-CSF
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Kansas Medical Center
Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer.
- Conditions
- Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03223753
- Testing
- Educational Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis
- Where
- 118 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- Children's Oncology Group
Lymphatic Diseases, Hematopoietic Malignancy
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units.
- Trial name
- NCT01451502
- Testing
- Umbilical Cord Blood (UCB)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stress, Psychological, Caregivers
Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
Background: People who have an allogeneic hematopoietic stem cell transplant (HSCT) need help as they recover. Being a caregiver can be stressful to the body and mind. Researchers want to find ways to reduce this stress.
- Trial name
- NCT02257853
- Testing
- Stress reduction intervention
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Peripheral T Cell Lymphoma
RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
This study is a single-center, single-arm, prospective phase II clinical trial that evaluates the efficacy and safety of an reduced-intensity conditioning (RIC) regimen with thiotepa combined with busulfan, fludarabine, and…
- Trial name
- NCT06468267
- Testing
- Thiotepa
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xianmin Song, MD
Bronchiolitis Obliterans Syndrome, Hematologic Malignancy
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
Lung is one of the target organs in chronic graft versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT05413356
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Leukemia, Graft Failure
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
Poor graft function (PGF) after allogeneic hematopoietic cell transplantation (allo-HCT) is a misunderstood complication associated with poor outcome and limited therapeutic options.
- Trial name
- REGALIA (NCT03948529)
- Testing
- eltrombopag
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Lille
Myelofibrosis, Chronic Myelomonocytic Leukemia
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse.
- Conditions
- Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT05233618
- Testing
- Tagraxofusp
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Karen Ballen, MD
Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
This phase II trial studies the side effect of busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem cell transplant.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder
- Trial name
- NCT02861417
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439227
- Testing
- Adavosertib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00806767
- Testing
- therapeutic immune globulin, busulfan, fludarabine phosphate
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes
Acute Myeloid Leukemia, Disorder Related to Bone Marrow Transplantation
Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
Early reduction of immunosuppressive agents after HLA matched donor transplantation can improve the survival of advanced stage acute myeloid leukemia. single-center, open clinical study
- Trial name
- NCT03150134
- Testing
- Cyclosporine, routine reduction of immunosuppressive drugs(cyclosporine)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Multiple Myeloma
Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation
The purpose of this study is to improve the efficacy of the HDC regimen by adding a novel, "targeted" means administering a variation of total body irradiation (TBI) radiation i.e., total skeletal irradiation (TSI) administered…
- Trial name
- NCT01182233
- Testing
- Total Skeletal Irradiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Rochester
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.